“Pro/ ‘Yes’ for PSA Testing Before BPO Surgical Therapy” Ignoring PSA in BPE is Not Progress; It’s Clinical Blindness
European Urology Focus · 2026-09 · 12 (4) · 628-630
DOI: 10.1016/j.euf.2026.04.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2026-09. Verfasst von Selcuk Guven und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey. Electronic address: selcukguven@hotmail.com. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Hyperplasia, Prostatic Neoplasms. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Although traditionally linked to prostate cancer screening, prostate-specific antigen (PSA) serves as a multifaceted clinical marker in men with lower urinary tract symptoms. PSA reflects prostate biology, predicts disease progression, and guides treatment decisions in benign prostatic enlargement. As a dynamic biomarker, changes in PSA over time indicate treatment response and disease course. PSA also facilitates oncological assessment, as enucleation reduces benign glandular interference and establishes a more reliable baseline for detecting incidental or future malignancy. Consequently, the clarity of PSA interpretation depends on the treatment approach, with complete adenoma removal yielding a more distinct clinical signal than tissue-ablative methods. PSA should be considered a continuous biomarker throughout the care pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey. Electronic address: selcukguven@hotmail.com.
- Department of Urology, Spital Thurgau AG, Kantonsspital Frauenfeld, Frauenfeld, Switzerland; Division of Urology, Department of Surgical Sciences, Stellenbosch University, Stellenbosch, Western Cape, South Africa; Hanno…
Zitieren
APA
Guven, S., & Herrmann, T. R. (2026). “Pro/ ‘Yes’ for PSA Testing Before BPO Surgical Therapy” Ignoring PSA in BPE is Not Progress; It’s Clinical Blindness. European Urology Focus, 12(4), 628-630. https://doi.org/10.1016/j.euf.2026.04.006
Vancouver
Guven S, Herrmann TR. “Pro/ ‘Yes’ for PSA Testing Before BPO Surgical Therapy” Ignoring PSA in BPE is Not Progress; It’s Clinical Blindness. European Urology Focus. 2026;12(4):628-630. doi:10.1016/j.euf.2026.04.006
BibTeX
@article{Guven2026,
author = {Guven, Selcuk and Herrmann, Thomas Rw},
title = {“Pro/ ‘Yes’ for PSA Testing Before BPO Surgical Therapy” Ignoring PSA in BPE is Not Progress; It’s Clinical Blindness},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {4},
pages = {628--630},
doi = {10.1016/j.euf.2026.04.006}
}
EUVIMED